Jump to Main Content
- Sun, Su Ming, et al. Show all 20 Authors
- Molecular cell 2016 v.63 no.3 pp. 514-525
- drugs; genotoxicity; humans; mutation; neoplasm cells; neoplasms; patients; phosphotransferases (kinases); therapeutics; tumor suppressor genes; yeasts
- ... An emerging therapeutic strategy for cancer is to induce selective lethality in a tumor by exploiting interactions between its driving mutations and specific drug targets. Here we use a multi-species approach to develop a resource of synthetic lethal interactions relevant to cancer therapy. First, we screen in yeast ∼169,000 potential interactions among orthologs of human tumor suppressor genes (T ...
- PubMed Central:
- Sun, Su, et al. Show all 8 Authors
- Environmental science and pollution research international 2018 v.25 no.4 pp. 3200-3208
- DNA damage; acetylcysteine; bisphenol A; bisphenol F; breast neoplasms; calcium; carcinogenesis; cell proliferation; cell viability; homeostasis; humans; neoplasm cells; reactive oxygen species; toxicity
- ... Reactive oxygen species (ROS) induced by bisphenol A (BPA) have been implicated in cellular oxidative damage and carcinogenesis. It is not known whether the potential alternatives of BPA, bisphenol AF (BPAF), and bisphenol F (BPF) can also induce ROS involved in mediating biological responses. This study evaluated the toxicity of BPAF and BPF on cell proliferation, DNA damage, intracellular calciu ...
- Sun, Su-ju, et al. Show all 13 Authors
- Anaerobe 2019 v.56 pp. 116-123
- Chinese people; Clostridium difficile; antibiotic resistance; death; diarrhea; digestive system; epidemiological studies; humans; infants; polymerase chain reaction; ribotypes
- ... Clostridioides difficile is a colonizer of the human gut; asymptomatic colonization has been reported to be more common in infants and is highly variable across regions even with no symptoms of diarrhea or death. Antibiotic treatment strategies might increase the antibiotic resistance of C. difficile. We performed a one-point study involving 1098 healthy infants (0–36 months) to address the defici ...